Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Trust Investment Advisors

Trust Investment Advisors cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,683 shares of the medical research company’s stock after selling 559 shares during the quarter. Trust Investment Advisors’ holdings in Edwards Lifesciences were worth $865,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baxter Bros Inc. lifted its stake in shares of Edwards Lifesciences by 3.0% in the 4th quarter. Baxter Bros Inc. now owns 87,824 shares of the medical research company’s stock worth $6,502,000 after acquiring an additional 2,556 shares during the period. TIAA Trust National Association increased its stake in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TIAA Trust National Association now owns 10,943 shares of the medical research company’s stock worth $810,000 after acquiring an additional 656 shares during the period. Prudential Financial Inc. raised its holdings in Edwards Lifesciences by 16.2% during the fourth quarter. Prudential Financial Inc. now owns 432,460 shares of the medical research company’s stock worth $32,015,000 after purchasing an additional 60,171 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Finally, Vanguard Group Inc. raised its stake in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.1 %

Shares of NYSE:EW opened at $71.29 on Wednesday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a 50-day simple moving average of $71.43 and a 200-day simple moving average of $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $41.91 billion, a P/E ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,303 shares of company stock worth $3,715,776 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Citigroup lifted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.